Friday, November 20, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > CEO Life > Health > Study finds Ozempic being sold for up to 400 times more than needed

Study finds Ozempic being sold for up to 400 times more than needed

in Health
Study finds Ozempic being sold for up to 400 times more than needed
Share on LinkedinShare on WhatsApp

A new research study has found that the drug Ozempic, used to treat diabetes and obesity, can be sold at a profit for less than $5, but instead manufacturer Novo Nordisk charges nearly $1,000 in the U.S.

Ozempic could be made for between 89 cents and $4.73 for a one-month supply, an amount that also includes a profit margin, researchers found. On a per-month basis, the study determined, the drug could be made for less than the diabetes drug insulin. Novo Nordisk would not share production costs for the drug nor Wegovy, its similar drug that treats obesity, but said that it is investing significantly to make sure that people have access to its drugs.

Senator Bernie Sanders (I-VT) blasted the company in a statement, saying “This outrageously high price has the potential to bankrupt Medicare, the American people and our entire health care system.” He called on Novo Nordisk to decrease the price of Ozempic to just $155 a month or lower, which is consistent with what the drug costs in other countries.

Novo Nordisk’s 2023 sales of Wegovy and Ozempic exceeded $18 billion. Bloomberg Law estimated that the patents linked to the drugs likely won’t expire until June 2033. The research found that Ozempic’s active ingredient, semaglutide, costs about 29 cents for a month’s supply. The cost of filling each pen is around 20 cents per month, while the other chemical ingredients cost around 15 center per monthly dose.

Tags: Bernie SandersBloomberg LawNovo NordiskOzempicSemaglutideWegovy

Related Posts

U.S. Loses Measles-Free Status After 26 Years
Health

U.S. Loses Measles-Free Status After 26 Years

To be successful in 2025, a therapist says do these 5 things: It works ‘any time of year’
Health

Why switching off from work is so hard

How to Fall Asleep in 10, 60, or 120 Seconds
Health

How to Fall Asleep in 10, 60, or 120 Seconds

High Carb Foods That Are Incredibly Healthy
Health

High Carb Foods That Are Incredibly Healthy

Why ‘Binge-Watching’ That TV Show Now May Affect Your Brain Later
Health

Why ‘Binge-Watching’ That TV Show Now May Affect Your Brain Later

Get Your Vitamin P: Why Pleasure Matters When It Comes to What You Eat
Health

Get Your Vitamin P: Why Pleasure Matters When It Comes to What You Eat

Can Collagen Really Improve Your Skin Health? What the Research Says
Health

Can Collagen Really Improve Your Skin Health? What the Research Says

What Type of Procrastinator Are You?
Health

What Type of Procrastinator Are You?

Stretches to Do Before Bed
Health

Stretches to Do Before Bed

Consumers Plan to Let Restaurants Do the Cooking During the Holidays
Health

How Staying Social Can Help to Prevent Dementia

No Result
View All Result

Recent Posts

  • Why are we so obsessed with the ’90s?
  • U.S. Loses Measles-Free Status After 26 Years
  • Plane clapping – joyful or deeply cringe?
  • The 4 themes shaping new manufacturing
  • Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.